Evaxion A/S (EVAX) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed outlook. Positive aspects include a solid cash position and business development pipeline, along with reduced losses. However, challenging financial markets, increased regulatory uncertainty, and dependency on partnerships pose significant risks. The Q&A session highlighted management's avoidance of specifics, adding uncertainty. Overall, the potential for partnerships and the Merck collaboration are positive, but the risks and uncertainties balance out, leading to a neutral sentiment.
Key Financial Performance
Cash Position $14.7 million at the end of June 2025, with an operating cash burn of approximately $14 million. This cash position is expected to fund operations until mid-2026. The cash position reflects project timing and is strengthened by the debt settlement agreement with the European Investment Bank.
Debt Settlement Agreement EUR 3.5 million of the total EUR 7 million loan was converted into equity, increasing equity by $4.1 million. This agreement simplifies the balance sheet, reduces liabilities, and improves cash flow.
Operating Loss $4.3 million in Q2 2025, compared to $4.6 million in Q2 2024. The reduction is mainly due to project timing.
Net Financial Expenses $0.7 million in Q2 2025, compared to $1.8 million in Q2 2024. The decrease is attributed to differences in derivative liability reassessments.
Net Loss $4.8 million in Q2 2025, compared to $6.2 million in Q2 2024. The reduction is primarily due to lower net financial expenses.
Total Equity $6.2 million at the end of June 2025, strengthened compared to the end of 2024 due to capital market activities and further strengthened by the debt settlement agreement in July 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
EVX-01: Personalized peptide-based cancer vaccine in Phase II clinical development for advanced melanoma. Two-year clinical efficacy data to be presented at ESMO Congress in October 2025. Extension phase for 3-year clinical outcome data initiated with minimal additional costs.
EVX-B4: Discovery program for a preventive vaccine against Group A Streptococcus. Initial computational analysis shows AI-Immunology can identify novel vaccine targets. Activities include testing novel antigens for immunogenicity and protection.
EVX-V1: Multicomponent vaccine for CMV infections in early preclinical development. Focus on lead antigen selection in the second half of 2025. Proprietary glycoprotein B antigen shows superior ability to neutralize the virus.
Partnership with MSD: On track for potential option exercise in the second half of 2025. Actively seeking partners for EVX-01 to advance clinical development.
Gates Foundation Grant: Received grant to design a subunit vaccine against polio using AI-Immunology. Project progressing as planned and generating significant attention to the platform.
Financial Position: Cash at hand of $14.7 million as of June 2025, funding operations until mid-2026. Operating cash burn expected to be $14 million for 2025.
Debt Conversion: Converted $4.1 million loan from the European Investment Bank into equity, simplifying balance sheet and reducing liabilities.
AI-Immunology Platform: Utilized for designing vaccines targeting cancer and infectious diseases. Demonstrates ability to identify novel vaccine targets and optimize known antigens.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Challenging financial markets: The company acknowledges that challenging financial markets are impacting deal execution, which could hinder their ability to secure partnerships or funding.
Increased regulatory uncertainty: Regulatory uncertainty is cited as a factor affecting deal execution, potentially delaying or complicating strategic initiatives.
Cash runway dependency: While the company has cash until mid-2026, its financial stability is contingent on achieving milestones like the MSD option exercise and securing new business development deals.
R&D cost increases: R&D project costs are expected to rise in the second half of 2025, which could strain financial resources if not offset by additional funding or revenue.
Dependence on partnerships: The company is actively seeking partners to advance its lead asset, EVX-01, through clinical development and registration, making its progress highly dependent on external collaborations.
Competitive pressures in vaccine development: The company operates in a highly competitive field, particularly in developing vaccines for diseases like melanoma, Group A Streptococcus, and CMV, where no approved vaccines currently exist.
Economic uncertainties: Broader economic uncertainties could impact the company's ability to raise funds or execute its strategic plans effectively.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Partnership with MSD: On track towards potential option exercise in the second half of 2025.
R&D Pipeline Progress: Significant progress in both Oncology and Infectious Disease programs. Key milestones include the EVX-01 Phase II trial extension for 3-year clinical outcome data and the addition of the EVX-B4 program for Group A Streptococcus vaccine development.
EVX-01 Cancer Vaccine: Upcoming 2-year clinical outcome data to be presented at the ESMO Congress in October 2025. Extension phase involves minimal additional costs and focuses on monotherapy to understand the vaccine's stand-alone effect. Plans to seek FDA advice for registration path.
EVX-B4 Program: Development of a preventive vaccine against Group A Streptococcus. Initial computational analysis shows promise, with ongoing and planned activities for testing novel antigens.
EVX-V1 Program: Development of a multicomponent vaccine for CMV infections. Heading towards lead antigen selection in the second half of 2025.
Financial Guidance: Cash runway extends until mid-2026, covering key milestones like the MSD option exercise and EVX-01 2-year data readout. Operational cash burn expected to be approximately $14 million for the full year 2025.
Business Development: Multiple parallel partnership discussions are ongoing, with business development remaining a key priority.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the remaining steps for Merck to decide on whether to option either or both of the programs?
A:The B3 collaboration has been running since September 2023, with exciting data generated. The timeline is on track, heading towards a conclusion in the second half of 2025. For B2, it is an evaluation collaboration with MSD conducting studies. This program is also on track, with a conclusion expected in the second half of 2025.
Q:Are the business development conversations primarily on the Infectious Disease side or is there Oncology interest?
A:The discussions span across the R&D pipeline and assets in both therapy areas, including target discovery collaborations using AI-Immunology. Some dialogues are more mature than others, but no specific details can be disclosed until contracts are signed.
Q:How will the 2-year data compare to the 1-year data for EVX-01, and how many patients from year 1 will be included in the 2-year data?
A:The 2-year data for EVX-01 has not yet been disclosed. Since the 1-year data, additional information and scans have been gathered. There are 11 active patients in the trial, many of whom are faring well.
Q:How many patients will be enrolled additionally in the third-year extension for EVX-01?
A:The extension phase involves a subset of patients who have consented to participate. They will receive 2 doses of EVX-01 without concomitant pembrolizumab treatment to study the mode of action. Specific numbers of patients have not yet been disclosed.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the number of patients in the third-year extension for EVX-01 and the exact nature of business development discussions, citing the need for signed contracts or further updates.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI Immunology
ESMO Congress
EUR
EVX program
European Investment
Evaxion share
GAS
Gates Foundation
Group Streptococcus
II trial
Immunology vaccine
Interim CEO
Investment Bank
Phase II
Rono Interim
agreement European
angle
cell antigen
difference
equity USD
glycoprotein entry
grant Gates
infection development
liability offering
life
loss period
path
polio
program vaccine
project plan
EVAX Transcript
Evaxion A/S (EVAX) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call summary and Q&A reveal mixed signals. While the company has promising programs and a solid cash runway until 2027, the lack of concrete partnership updates and unproven scalability of the AI-Immunology platform pose risks. The financial performance is stable, but not exceptional, with a net loss in line with expectations. The operational changes and strategic focuses are promising but yet to show results. Given these factors, the stock is likely to remain stable over the next two weeks, resulting in a neutral rating.
Evaxion A/S (EVAX) Q4 2025 Earnings Call Transcript
Positive3-6
The earnings call summary and Q&A indicate a positive outlook for Evaxion. The financial performance shows improved revenue and reduced operational costs, leading to a better financial position. The extended cash runway and strengthened equity are positive indicators. Product development, particularly the progress of EVX-01 and potential of EVX-04, is promising. The AI-Immunology platform enhancements and ongoing partnerships add further optimism. Despite some uncertainties in responses, the overall sentiment is positive, suggesting a likely stock price increase in the short term.
Evaxion A/S (EVAX) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call highlights positive financial performance with a cash runway extended to 2027 and revenue from MSD. Significant progress in R&D, particularly in oncology and infectious diseases, enhances the company's growth prospects. While there are potential risks in partnerships and production, the overall sentiment is positive, supported by optimistic guidance and ongoing partnership discussions. The Q&A section reveals strong interest in the company's pipeline and technology, further boosting confidence. Despite some uncertainties, the overall outlook is positive, suggesting a potential stock price increase of 2% to 8%.
Evaxion A/S (EVAX) Q2 2025 Earnings Call Transcript
Unknown8-19
The earnings call presents a mixed outlook. Positive aspects include a solid cash position and business development pipeline, along with reduced losses. However, challenging financial markets, increased regulatory uncertainty, and dependency on partnerships pose significant risks. The Q&A session highlighted management's avoidance of specifics, adding uncertainty. Overall, the potential for partnerships and the Merck collaboration are positive, but the risks and uncertainties balance out, leading to a neutral sentiment.
EVAX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
